Cytiva, a global life sciences leader, and ForecyteBio, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), are sharing expertise and advanced technology to bring better speed and efficiency to the CGT industry in China and the United States.

The two companies’ collaboration starts in Cytiva’s Fast Trak center in Shanghai, where biotech companies can quickly access industry know-how and get professional consulting and training. This will allow Forecyte Bio to launch its CDMO business quickly to win in the competitive market. With the installation of Cytiva’s FlexFactory platforms, Forecyte Bio will have good manufacturing practice (GMP) production capabilties for virus and plasmid DNA in Shanghai, China and Maryland, United States.

Lihua Yu, General Manager of Cytiva in Greater China, says: "Cytiva’s end-to-end solutions and customer-centric mindset are the foundation of this collaboration. Our vision is a world in which access to life-changing therapies transforms human health. I believe that the collaboration with Forecyte Bio will lead us one step closer to this.”

Yingke He, Founder and CEO of Forecyte Bio, says: “The collaboration will accelerate the standardization of processes in the CGT CDMO and promote the development of the industry. It will also help us offer a “one-stop” holistic service package to clients and ultimately improve patient access to cell and gene therapies.”

As biotechnology has achieved continuous breakthroughs, the expansion of the CGT industry is driving the growth of CDMOs. According to the research of Frost & Sullivan, the global CGT CDMO market is likely to reach $10.11 billion by 2026.